EUVIMEDEUVIMED entdecken
Crossref

Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product

Tilman Lechel, Ruben Silva Otero, Andreas Springer, Anja Rutkowski, Dominik Matzkow, Johannes Zart, Tobias Hartmann, Dieter Hochhuth

Journal of Pharmaceutical and Biomedical Analysis · 2024

DOI: 10.1016/j.jpba.2024.116282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2024. Verfasst von Tilman Lechel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH, Stieffring 14, Berlin 13627, Germany. Hauptthemen laut MEDLINE: Cabergoline, Oxidation-Reduction, Ergolines, Drug Stability. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabergoline is a dopamine agonist with applications as anti-Parkinson drug and prolactin inhibitor. The cabergoline drug product Laktostop® 50 µg/mL is used in veterinary medicine for lactation suppression in cats and dogs e.g. during false pregnancy. Recently, during ongoing HPLC stability testing of Laktostop® 50 µg/mL a new oxidation product of Cabergoline was identified. A synthesis starting from Cabergoline was developed, followed by full characterization of the unknown impurity. Preliminary HPLC and LC-MS analyses indicated the unknown impurity as mono-oxygenated product of Cabergoline (Cabergoline N-oxide) that is presumably formed with oxygen by a radical mechanism. Thus, Cabergoline was treated with oxidizing agents such as m-chloroperoxybenzoic acid to afford the desired Cabergoline-N-oxide as a byproduct. After isolation by column chromatography, NMR and LC-MS-MS studies provided evidence that oxidation occurred at the N-allyl nitrogen of Cabergoline to form Cabergoline-N-oxide. © 1905 Elsevier Science. All rights reserved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CabergolineOxidation-ReductionErgolinesDrug StabilityTandem Mass SpectrometryChromatography, High Pressure LiquidMagnetic Resonance SpectroscopyDopamine AgonistsDrug ContaminationChromatography, Liquid

Stichwörter der Autor:innen

CabergolineCabergoline N-oxideDrug impurityOxidationStructure evaluation

Substanzen

CabergolineErgolinesDopamine Agonists

Autor:innen und Institutionen

  • Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH, Stieffring 14, Berlin 13627, Germany.
  • Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH, Stieffring 14, Berlin 13627, Germany. Electronic address: ruben.silva-otero@cpl-sachse.de.
  • CoreFacility BioSupraMol, Institut für Chemie und Biochemie, Fachbereich Biologie, Chemie, Pharmazie, Freie Universität Berlin, Takustrasse 3, Berlin 14195, Germany.
  • CP-Pharma Handelsgesellschaft mbH, Ostlandring 13, Burgdorf 31303, Germany.

Zitieren

APA

Lechel, T., Silva Otero, R., Springer, A., Rutkowski, A., Matzkow, D., Zart, J., Hartmann, T., & Hochhuth, D. (2024). Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116282

Vancouver

Lechel T, Silva Otero R, Springer A, Rutkowski A, Matzkow D, Zart J, et al. Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product. Journal of Pharmaceutical and Biomedical Analysis. 2024. doi:10.1016/j.jpba.2024.116282

BibTeX
@article{Lechel2024,
  author = {Lechel, Tilman and Silva Otero, Ruben and Springer, Andreas and Rutkowski, Anja and Matzkow, Dominik and Zart, Johannes and Hartmann, Tobias and Hochhuth, Dieter},
  title = {Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product},
  journal = {Journal of Pharmaceutical and Biomedical Analysis},
  year = {2024},
  doi = {10.1016/j.jpba.2024.116282}
}
Kostenlos starten →